Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity : A Real-Life Perspective
Dupilumab is currently approved for the treatment of Type 2 severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Few studies have specifically reported on dupilumab efficacy on asthma outcomes as a primary objective in a real-life setting, in patients with and without CRSwNP. Our study aimed to explore the efficacy of dupilumab on functional, inflammatory, and patient-reported outcomes in asthma patients across different disease phenotypes and severity, including mild-to-moderate asthma coexisting with CRSwNP. Data from 3, 6, and 12 months follow-up were analyzed. Asthma (FEV1%, Tiffeneau%, ACT, FeNO, oral steroid use, exacerbation rate, and blood eosinophilia) and polyposis (SNOT22, VAS, NPS) outcomes showed a rapid (3 months) and sustained (6 and 12 months) significant change from baseline, despite most of the patients achieving oral steroid withdrawal. According to the sensitivity analysis, the improvement was not conditioned by either the presence of polyposis or severity of asthma at baseline. Of note, even in the case of milder asthma forms, a significant further improvement was recorded during dupilumab treatment course. Our report provides short-, medium-, and long-term follow-up data on asthma outcomes across different diseases phenotypes and severity, contributing to the real-world evidence related to dupilumab efficacy on upper and lower airways T2 inflammation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Biomedicines - 12(2024), 2 vom: 08. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Caminati, Marco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Asthma |
|---|
| Anmerkungen: |
Date Revised 27.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/biomedicines12020390 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368879755 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368879755 | ||
| 003 | DE-627 | ||
| 005 | 20240229164652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/biomedicines12020390 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1309.xml |
| 035 | |a (DE-627)NLM368879755 | ||
| 035 | |a (NLM)38397992 | ||
| 035 | |a (PII)390 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Caminati, Marco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity |b A Real-Life Perspective |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Dupilumab is currently approved for the treatment of Type 2 severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Few studies have specifically reported on dupilumab efficacy on asthma outcomes as a primary objective in a real-life setting, in patients with and without CRSwNP. Our study aimed to explore the efficacy of dupilumab on functional, inflammatory, and patient-reported outcomes in asthma patients across different disease phenotypes and severity, including mild-to-moderate asthma coexisting with CRSwNP. Data from 3, 6, and 12 months follow-up were analyzed. Asthma (FEV1%, Tiffeneau%, ACT, FeNO, oral steroid use, exacerbation rate, and blood eosinophilia) and polyposis (SNOT22, VAS, NPS) outcomes showed a rapid (3 months) and sustained (6 and 12 months) significant change from baseline, despite most of the patients achieving oral steroid withdrawal. According to the sensitivity analysis, the improvement was not conditioned by either the presence of polyposis or severity of asthma at baseline. Of note, even in the case of milder asthma forms, a significant further improvement was recorded during dupilumab treatment course. Our report provides short-, medium-, and long-term follow-up data on asthma outcomes across different diseases phenotypes and severity, contributing to the real-world evidence related to dupilumab efficacy on upper and lower airways T2 inflammation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a asthma | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a chronic rhinosinusitis with nasal polyps | |
| 650 | 4 | |a dupilumab | |
| 650 | 4 | |a lung function | |
| 650 | 4 | |a real-life | |
| 700 | 1 | |a Maule, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Benoni, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Bagnasco, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Beghè, Bianca |e verfasserin |4 aut | |
| 700 | 1 | |a Braido, Fulvio |e verfasserin |4 aut | |
| 700 | 1 | |a Brussino, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Cameli, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Candeliere, Maria Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Carpagnano, Giovanna Elisiana |e verfasserin |4 aut | |
| 700 | 1 | |a Costanzo, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Crimi, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a D'Amato, Mariella |e verfasserin |4 aut | |
| 700 | 1 | |a Del Giacco, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Guarnieri, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Yacoub, Mona-Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Micheletto, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Nicola, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Olivieri, Bianca |e verfasserin |4 aut | |
| 700 | 1 | |a Pini, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Schiappoli, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Vaia, Rachele |e verfasserin |4 aut | |
| 700 | 1 | |a Vianello, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Visca, Dina |e verfasserin |4 aut | |
| 700 | 1 | |a Spanevello, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Senna, Gianenrico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicines |d 2013 |g 12(2024), 2 vom: 08. Feb. |w (DE-627)NLM268899797 |x 2227-9059 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:2 |g day:08 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/biomedicines12020390 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 2 |b 08 |c 02 | ||